NCT00307684
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
See it on ClinicalTrials.gov ↗155 people
45.8%
54.2%
71 womenmiddle line = equal numbers84 men
- Phase
- PHASE3
- Paid for by
- Janssen-Cilag International NV
- Finished
- 2008-07
- Health conditions
- Attention Deficit Disorder With Hyperactivity
- Who could join
- Anyone
- Ages
- 18 Years – 65 Years
- Average age
- mean 35.0 years
- Age 65+
- Not reported
- Weight (BMI)
- mean 24.8 kg/m2
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 98.7% · Black / African American 1.3%
Women left out
- No seizures
Women with epilepsy or past seizures were turned away.
“…pressants (unless patient has been on a stable dosage during the 42603ATT3002 trial, in which case treatment may continue as long as dosage remains unchanged for the duration of the study) or mood stabilisers (e.g. anti-epileptics, lithium)”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Any clinically unstable psychiatric condition including but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), Anti-social personality disorder, borderline personality disorder”
Study titles and rules are shown in their original English.